BH4 Blood Levels Variations in Pre Eclamptic Women

Acute Renal Failure Clinical Trial

— BH4P  

Official title:

Can bh4 Levels Predict Severity and Complications of Pre Eclampsia in Pregnant Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05847361
• Other study ID #: Tunis Elmanar university
• Status: Completed
• Start date: March 15, 2023
• Est. completion date: December 6, 2023

Study information

• Verified date: December 2023
• Source: University Tunis El Manar
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

tetrahydrobiopterin (BH4) is degraded by several enzymes, including BH4 oxidase and peroxidases. Several factors can affect its synthesis and degradation. BH4 deficiency or depletion and genetic variations in the genes involved in BH4 metabolism have been associated with hypertension, suggesting that BH4 may play a role in the pathogenesis of hypertension. The maternity center of Tunis ( CMNT ) is a level 3 maternity center, supporting over 12 000 births yearly, where the caesarean section's rate is very high, close to 45% of deliveries. Early detection of these patients can help control maternal and neonatal safety outcomes. we can avoid complications such as severe preeclampsia, HELLP syndrom and eclampsia for the mother, and preterm delievery and fetal growth restriction for the new born. in the literature, studies have reported a decrease in BH4 levels in pregnant women compared to non-pregnant women and others showed that its deficiency or depletion has been associated with hypertension. Moreover, tetrahydrobiopterin administration has been studied as a potential treatment for preeclampsia but the optimal dose has not yet been determined, and further studies are needed to determine the appropriate dose, timing, and duration of BH4 supplementation in this context. Thus, BH4 blood levels as a mean of screening, could enrich our diagnostic arsenal. The purpose of our study is to compare BH4 levels between preeclamptic and normotensive women.

Description:

The investigators will conduct a monocentric , prospective, observational study, including 300 pregnant women (150 normotensive and 150 preeclamptic). The participants will be divided into 2 equal groups : - Group P : Preclampsia - Group N : Normotensive After written and informed consent are obtained, a standard battery of blood tests including serum BH4 will be runned for the eligible patients at any moment from the admission to the end of the pregnancy. Baseline data will be collected at enrollment, including demographic and medical history information, blood pressure, proteinuria, and blood samples for BH4 and other biomarker measurements. Follow-up data will be collected at delivery, including blood pressure, proteinuria, and fetal growth measurements, as well as maternal and neonatal outcomes; After collecting all groups, blood samples will be analysed for BH4.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: December 6, 2023
• Est. primary completion date: July 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women aged over 18 YEARS
• informed consent
• Pregnant
• Term of pregnancy over than 24 weeks of gestation
• Having a normal pregnancy ( for the control group)
• Being diagnosed with preeclampsia or severe preeclampsia as defined in international guidelines (for the case group)

Non- inclusion Criteria:

• Women with known phenylketonuria
• Any history of ( treated or not) hypertension prior to the current pregnancy
• Any history of ( treated or not) diabetes or gestational diabetes during the current pregnancy
• Any history of renal failure or kidney injury) in the current pregnancy
• Women under long-term medications for arterial hypertension or before 24 week of the current pregnancy

Related Conditions & MeSH terms

• Abruptio Placentae
• Acute Kidney Injury
• Acute Renal Failure
• Eclampsia
• Eclampsia, Antepartum
• HELLP Syndrome
• Pre Eclampsia
• Pre-Eclampsia
• Pregnancy Complications

Intervention

Diagnostic Test:
• BH4 blood level
from admission to END OF PREGNANCY, a blood sample is taken.

Locations

Country	Name	City	State
Tunisia	Tunis maternity and neonatology center, minisetry of public health	Tunis

Sponsors (1)

Lead Sponsor	Collaborator
University Tunis El Manar

Country where clinical trial is conducted

Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	the association between BH4 blood level (ng/mL) and preterm delivery (before 37 weeks of pregnancy)	Secondary outcome measures will include the predectivity of preterm delivery with BH4 levels	From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Other	the association between BH4 blood level (ng/mL) and fetal growth restriction.	Secondary outcome measures will include the association between BH4 levels and fetal growth restriction.	From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Other	the association between BH4 blood level (ng/mL) and placenta abroptio	econdary outcome measures will include the association between BH4 levels and placenta abroptio	From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Other	the association between BH4 blood level (ng/mL) and mortality	predectivity of maternal and foetal mortality by BH4 levels	From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Primary	the association between BH4 blood level (ng/mL) and severity of preeclampsia (biological and clinical criteria)	The primary outcome measure will be the association between BH4 levels and the severity of preeclampsia, including maternal and fetal complications Preeclampsia is defined by : Systolic blood pressure (SBP) higher than 140 mmHg or/and diastolic blood pressure (DBP)higher than 90 mmHg whith proteinuria higher than 0.3 g/24 h; Its sevrity is defined by at least one of those criteria: SBP > 160 mmHg and/or DBP >110 mmHg; proteinuria > 3g/24h; creatini level > 90 µmol/ l; oliguria < 500 ml /24 hours or < 25 ml/ h; thrombocytopenia < 100.000/mm3; Cytolysis > two times the normal value; neurosensory signs; chest pain , acute lung edema, dyspnea	From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Secondary	the association between BH4 blood level (ng/mL) and gestational hypertension.	Secondary outcome measures will include the associationtion between BH4 levels and gestational hypertension.; gestational hypertension are defined by High Blood pressure SBP > 160 mmHg and/or DBP > 90 mmHg without proteinuria or any other preeclamptic criteria	From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)